Stereotactic radiofrequency ablation of a variety of liver masses in children.
Adenoma
echinococcosis
hepatoblastoma
hepatocellular carcinoma
metastatic tumor
Journal
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
ISSN: 1464-5157
Titre abrégé: Int J Hyperthermia
Pays: England
ID NLM: 8508395
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
21
9
2020
pubmed:
22
9
2020
medline:
25
6
2021
Statut:
ppublish
Résumé
Surgical resection is currently the cornerstone of liver tumor treatment in children. In adults radiofrequency ablation (RFA) is an established minimally invasive treatment option for small focal liver tumors. Multiprobe stereotactic RFA (SRFA) with intraoperative image fusion to confirm ablation margins allows treatment for large lesions. We describe our experience with SRFA in children with liver masses. SRFA was performed in 10 patients with a median age of 14 years (range 0.5-17.0 years) suffering from liver adenoma ( The technical success rate was 100%, as was the survival rate. No transient adverse effects higher than grade II (Clavien and Dindo) were encountered after interventions. The median hospital stay was 5 d (range 2-33 d). In two patients who subsequently underwent transplant hepatectomy complete ablation was histologically confirmed. Follow-up imaging studies (median 55 months, range 18-129 months) revealed no local or distant recurrence of disease in any patient. SRFA is an effective minimal-invasive treatment option in pediatric patients with liver tumors of different etiologies.
Sections du résumé
BACKGROUND AND AIMS
Surgical resection is currently the cornerstone of liver tumor treatment in children. In adults radiofrequency ablation (RFA) is an established minimally invasive treatment option for small focal liver tumors. Multiprobe stereotactic RFA (SRFA) with intraoperative image fusion to confirm ablation margins allows treatment for large lesions. We describe our experience with SRFA in children with liver masses.
METHODS
SRFA was performed in 10 patients with a median age of 14 years (range 0.5-17.0 years) suffering from liver adenoma (
RESULTS
The technical success rate was 100%, as was the survival rate. No transient adverse effects higher than grade II (Clavien and Dindo) were encountered after interventions. The median hospital stay was 5 d (range 2-33 d). In two patients who subsequently underwent transplant hepatectomy complete ablation was histologically confirmed. Follow-up imaging studies (median 55 months, range 18-129 months) revealed no local or distant recurrence of disease in any patient.
CONCLUSIONS
SRFA is an effective minimal-invasive treatment option in pediatric patients with liver tumors of different etiologies.
Identifiants
pubmed: 32954876
doi: 10.1080/02656736.2020.1822549
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM